Jaime Almandoz, MD, MBA, of UT Southwestern Medical Center, speaks on results of a study that investigated tirzepatide uptake ...

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

"With the FDA announcing the resolution of shortages for Semaglutide (Wegovy, Ozempic) and Tirzepatide (Zepbound, Mounjaro), compounding pharmacies must halt production of these medications. This ...

Tirzepatide is the active ingredient in Zepbound, approved by the Food and Drug Administration (FDA) specifically for weight loss. Semaglutide was initially approved under the brand name Ozempic ...

After approval, tirzepatide dispensations increased markedly among adults with type 2 diabetes prescribed glucose-lowering ...

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

In this retrospective cohort study, tirzepatide dispensations were found to have increased significantly following approval ...

Among all antiobesity medications, the incremental cost-effectiveness ratios were $197,023 and $467,676 per quality-adjusted life-year for tirzepatide and semaglutide, respectively. HealthDay News ...

Current Status of GLP-1 Medications The FDA has officially determined that the shortage of both semaglutide and tirzepatide injection products is now resolved. Semaglutide: The FDA determined on ...

Sharp increases were seen in dispensations of tirzepatide (0.0 to 40.6%) and semaglutide (2.4 mg; 0.0 to 32.2%) among adults without diabetes but prescribed WLMs; the most frequently dispensed WLM ...